Also, Vismodegib- or NVP-LDE225- (SMO/SHH pathway inhibitors) resistant BCCs patients and mouse medulloblastoma cells have been shown to acquire mutations in SUFU or amplification of a downstream transcriptional effector of the SHH signaling pathway, GLI2 [16, 19] (Figure 2). Here, GLI2 is linked to medulloblastoma.